Novartis AG (NVS): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Novartis ( NVS) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.5%. By the end of trading, Novartis fell 93 cents (-1.3%) to $68.60 on light volume. Throughout the day, 1.2 million shares of Novartis exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in price between $68.48-$68.98 after having opened the day at $68.89 as compared to the previous trading day's close of $69.53. Other companies within the Drugs industry that declined today were: Spectrum Pharmaceuticals ( SPPI), down 37.3%, PharmAthene ( PIP), down 9.6%, Oxygen Biotherapeutics ( OXBT), down 9.4%, and Geron Corporation ( GERN), down 9.2%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $167 billion and is part of the health care sector. The company has a P/E ratio of 17.7, equal to the S&P 500 P/E ratio of 17.7. Shares are up 9.8% year to date as of the close of trading on Tuesday. Currently there are six analysts that rate Novartis a buy, one analyst rates it a sell, and three rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, iBio ( IBIO), up 15.4%, Amicus Therapeutics ( FOLD), up 8.1%, Sunesis Pharmaceuticals ( SNSS), up 7.4%, and Simcere Pharmaceutical Group ( SCR), up 6.7%, were all gainers within the drugs industry with Incyte ( INCY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Novartis CEO Joe Jimenez to Step Down in 2018

FDA Greenlights Novartis' Gene Therapy for Leukemia

Novartis' CAR-T Gene Therapy Receives FDA Approval

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)